Neoadjuvant therapy for pancreatic cancer: the Duke experience
- 1 October 2004
- journal article
- review article
- Published by Elsevier BV in Surgical Oncology Clinics of North America
- Vol. 13 (4), 675-684
- https://doi.org/10.1016/j.soc.2004.06.001
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialThe Lancet, 2001
- Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicatorsJournal of Gastrointestinal Surgery, 2000
- Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinomaThe American Journal of Surgery, 2000
- Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary RegionAnnals of Surgery, 1999
- Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves SurvivalAnnals of Surgery, 1997
- Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5 fluorouracilInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Adjuvant therapy of resected adenocarcinoma of the pancreasInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancerCancer, 1987
- Pancreatic CancerArchives of Surgery, 1985